WO1998010767A3 - Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders - Google Patents

Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders Download PDF

Info

Publication number
WO1998010767A3
WO1998010767A3 PCT/US1997/016145 US9716145W WO9810767A3 WO 1998010767 A3 WO1998010767 A3 WO 1998010767A3 US 9716145 W US9716145 W US 9716145W WO 9810767 A3 WO9810767 A3 WO 9810767A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
skin disorders
manufacture
treatment
hyperproliferative skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/016145
Other languages
French (fr)
Other versions
WO1998010767A9 (en
WO1998010767A2 (en
Inventor
Gerald Mcmahon
Laura Kay Shawver
Blair Narog
Peng Cho Tang
Klaus Peter Hirth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Priority to EP97941542A priority Critical patent/EP0954315A2/en
Priority to AU43429/97A priority patent/AU4342997A/en
Priority to CA002265630A priority patent/CA2265630A1/en
Publication of WO1998010767A2 publication Critical patent/WO1998010767A2/en
Publication of WO1998010767A9 publication Critical patent/WO1998010767A9/en
Publication of WO1998010767A3 publication Critical patent/WO1998010767A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention is directed to methods and compositions for treating hyperproliferative skin disorders utilizing a quinazoline derivative as an active ingredient.
PCT/US1997/016145 1996-09-13 1997-09-11 Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders Ceased WO1998010767A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97941542A EP0954315A2 (en) 1996-09-13 1997-09-11 Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
AU43429/97A AU4342997A (en) 1996-09-13 1997-09-11 Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
CA002265630A CA2265630A1 (en) 1996-09-13 1997-09-11 Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US2606796P 1996-09-13 1996-09-13
US60/026,067 1996-09-13
US3143696P 1996-11-20 1996-11-20
US60/031,436 1996-11-20
US3498197P 1997-01-08 1997-01-08
US60/034,981 1997-01-08
US4837297P 1997-06-03 1997-06-03
US60/048,372 1997-06-03

Publications (3)

Publication Number Publication Date
WO1998010767A2 WO1998010767A2 (en) 1998-03-19
WO1998010767A9 WO1998010767A9 (en) 1998-07-02
WO1998010767A3 true WO1998010767A3 (en) 1998-08-06

Family

ID=27487474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/016145 Ceased WO1998010767A2 (en) 1996-09-13 1997-09-11 Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders

Country Status (4)

Country Link
EP (1) EP0954315A2 (en)
AU (1) AU4342997A (en)
CA (1) CA2265630A1 (en)
WO (1) WO1998010767A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160889B2 (en) 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
USRE42353E1 (en) 1996-09-25 2011-05-10 Astrazeneca Uk Limited Quinazoline derivatives and pharmaceutical compositions containing them

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
ES2169355T3 (en) 1996-03-05 2002-07-01 Astrazeneca Ab DERIVATIVES OF 4-ANILINOQUINAZOLINA.
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
EP1294349A2 (en) * 2000-06-26 2003-03-26 The Regents Of The University Of Michigan Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin
AU2002217999A1 (en) 2000-11-01 2002-05-15 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
LT2762140T (en) 2001-02-19 2017-06-26 Novartis Ag Treatment of solid brain tumours with a rapamycin derivative
BR0209647A (en) 2001-05-16 2004-07-27 Novartis Ag A combination comprising n- {5- [4- (4-methyl-piperazine-methyl) -benzoylamido] -2-methyl-phenyl} -4- (3-pyridyl) -2-pyrimidine-amine and a chemotherapeutic agent
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
CA2483594C (en) 2002-05-16 2011-02-15 Novartis Ag Use of edg receptor binding agents in cancer
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
RS52545B (en) 2004-04-07 2013-04-30 Novartis Ag INHIBITORI PROTEIN APOPTOZE (IAP)
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CA2592971A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Method of treating brain cancer
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
EP2275103B1 (en) 2005-11-21 2014-04-23 Novartis AG mTOR inhibitors in the treatment of endocrine tumors
AU2007218725B2 (en) 2006-02-21 2011-12-01 Eisai R & D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
JP2009532503A (en) 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト Combination of therapeutic agents for treating cancer
CN102861338A (en) 2006-04-05 2013-01-09 诺瓦提斯公司 Combinations of comprising a bcr-abl, c-kit and pdgf-r tyrosine kinase inhibitor used for treating cancer
US20090317489A1 (en) 2006-05-09 2009-12-24 Hanspeter Nick Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof
KR20090073121A (en) 2006-09-29 2009-07-02 노파르티스 아게 Pyrazolopyrimidines as PI3 'Lipid Kinase Inhibitors
EP2491923A3 (en) 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
US8530654B2 (en) 2007-02-16 2013-09-10 Eisai R&D Management Co., Ltd. Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid
CN101687819B (en) 2007-08-17 2013-03-20 卫材R&D管理有限公司 topical agent
CN101687820B (en) 2007-08-17 2012-07-25 卫材R&D管理有限公司 The manufacture method of quinazoline derivative
AU2009228765B2 (en) 2008-03-24 2012-05-31 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
PT2260020E (en) 2008-03-26 2014-10-28 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
ES2704986T3 (en) 2008-10-16 2019-03-21 Celator Pharmaceuticals Inc Combinations of a water-soluble liposomal camptothecin with cetuximab or bevacizumab
EP2379499B1 (en) 2008-12-18 2014-04-09 Novartis AG Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid
AU2009327405A1 (en) 2008-12-18 2011-06-30 Novartis Ag New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
RS53041B (en) 2008-12-18 2014-04-30 Novartis Ag 1- [4- [1- (4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXYIMINO) -ETHYL] -2-ETHYL-BENZYL] -AZETIDINE-3-CARBOXYLIC ACID
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
PL2391366T3 (en) 2009-01-29 2013-04-30 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
MA33451B1 (en) 2009-06-26 2012-07-03 Novartis Ag 1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS CYP INHIBITORS 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (en) 2009-08-12 2012-09-28 Новартис Аг HETEROCYCLIC HYDRAZONES AND THEIR APPLICATION FOR THE TREATMENT OF CANCER AND INFLAMMATION
MY162604A (en) 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
MX2012002179A (en) 2009-08-20 2012-03-16 Novartis Ag Heterocyclic oxime compounds.
AU2010288534A1 (en) 2009-08-26 2012-03-15 Novartis Ag Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators
AU2010294209A1 (en) 2009-09-10 2012-03-29 Irm Llc Ether derivatives of bicyclic heteroaryls
MY156209A (en) 2009-11-04 2016-01-29 Novartis Ag Heterocyclic sulfonamide derivatives useful mek inhibitors
EP2503888A4 (en) 2009-11-23 2015-07-29 Cerulean Pharma Inc CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC ADMINISTRATION
WO2011064211A1 (en) 2009-11-25 2011-06-03 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
AU2012265844A1 (en) 2009-12-08 2013-05-02 Novartis Ag Heterocyclic sulfonamide derivatives
JP5456908B2 (en) 2009-12-08 2014-04-02 ノバルティス アーゲー Heterocyclic sulfonamide derivatives
CU24130B1 (en) 2009-12-22 2015-09-29 Novartis Ag ISOQUINOLINONES AND REPLACED QUINAZOLINONES
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
EP2582681A1 (en) 2010-06-17 2013-04-24 Novartis AG Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CN102947274A (en) 2010-06-17 2013-02-27 诺瓦提斯公司 Biphenyl substituted 1,3-dihydro-benzimidazol-2-ylideneamine derivatives
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
JP2013537210A (en) 2010-09-16 2013-09-30 ノバルティス アーゲー 17α-hydroxylase / C17,20-lyase inhibitor
KR20130130030A (en) 2010-12-21 2013-11-29 노파르티스 아게 Bi-heteroaryl compounds as vps34 inhibitors
JP2014505088A (en) 2011-02-10 2014-02-27 ノバルティス アーゲー [1,2,4] Triazolo [4,3-b] pyridazine compounds as C-MET tyrosine kinase inhibitors
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
CN103492390A (en) 2011-03-08 2014-01-01 诺瓦提斯公司 Fluorophenyl bicyclic heteroaryl compounds
EA023064B1 (en) 2011-04-28 2016-04-29 Новартис Аг 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
CA2840315A1 (en) 2011-06-27 2013-01-03 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
EP2758043A4 (en) 2011-08-17 2016-02-24 Dennis M Brown COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS, IN PARTICULAR SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL
UY34329A (en) 2011-09-15 2013-04-30 Novartis Ag TRIAZOLOPIRIDINE COMPOUNDS
US8969341B2 (en) 2011-11-29 2015-03-03 Novartis Ag Pyrazolopyrrolidine compounds
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
MY170922A (en) 2011-12-22 2019-09-18 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
US9126979B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
CN104136429A (en) 2011-12-23 2014-11-05 诺华股份有限公司 Compounds for inhibiting the interaction of bcl2 with binding partners
AU2012355615A1 (en) 2011-12-23 2014-07-10 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
CN104125953A (en) 2011-12-23 2014-10-29 诺华股份有限公司 Compounds for inhibiting interaction of bcl2 with binding partners
CN104125955A (en) 2011-12-23 2014-10-29 诺华股份有限公司 Compounds for inhibiting interaction of bcl2 with binding partners
JO3357B1 (en) 2012-01-26 2019-03-13 Novartis Ag Imidazopyrrolidinone compounds
CN110507654A (en) 2012-04-03 2019-11-29 诺华有限公司 Combination with tyrosine kinase inhibitors and use thereof
JP6171003B2 (en) 2012-05-24 2017-07-26 ノバルティス アーゲー Pyrrolopyrrolidinone compounds
WO2013188763A1 (en) 2012-06-15 2013-12-19 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
WO2014025395A1 (en) 2012-08-06 2014-02-13 Duke University Compounds and methods for targeting hsp90
CA2888803A1 (en) 2012-11-05 2014-05-08 Jooeun Bae Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
TW201422625A (en) 2012-11-26 2014-06-16 Novartis Ag Solid form of dihydro-pyrido-oxazine derivative
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
LT2958943T (en) 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania CANCER TREATMENT USING HUMANIZED ANTI-EGFRVIII CHIMERY ANTIGEN RECEPTOR
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc Combination of kinase inhibitors and uses thereof
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (en) 2013-07-24 2015-02-27 Novartis Ag SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
EP3046921A4 (en) 2013-09-22 2017-02-22 Calitor Sciences, LLC Substituted aminopyrimidine compounds and methods of use
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2015148714A1 (en) 2014-03-25 2015-10-01 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
JP6517319B2 (en) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ Substituted heteroaryl compounds and methods of use
RU2016140160A (en) 2014-04-03 2018-05-07 Инвиктус Онколоджи Пвт. Лтд. SUPRAMOLECULAR COMBINATOR MEDICINES
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (en) 2014-07-31 2017-03-31 노파르티스 아게 Combination therapy
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
US11261187B2 (en) 2016-04-22 2022-03-01 Duke University Compounds and methods for targeting HSP90
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
US20190209669A1 (en) 2016-08-23 2019-07-11 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
RU2019112860A (en) 2016-09-27 2020-10-30 Серо Терапьютикс, Инк. CHIMERIC INTERNALIZING RECEPTOR MOLECULES
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
AU2018341244A1 (en) 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. Peptide vaccines and hdac inhibitors for treating multiple myeloma
US12059463B2 (en) 2017-10-24 2024-08-13 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
AU2017444054B2 (en) 2017-12-21 2021-10-07 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Class of pyrimidine derivative kinase inhibitors
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
EP3774865A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
MX2020010235A (en) 2018-03-28 2020-10-28 Cero Therapeutics Inc EXPRESSION VECTORS FOR CHIMERIC ENGINEERING RECEPTORS, GENETICALLY MODIFIED HOST CELLS AND USES THEREOF.
EP3826988A4 (en) 2018-07-24 2023-03-22 Hygia Pharmaceuticals, LLC COMPOUNDS, DERIVATIVES AND ANALOGS AGAINST CANCER
WO2021067875A1 (en) 2019-10-03 2021-04-08 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
WO2021185844A1 (en) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021233534A1 (en) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
EP4136228A4 (en) 2020-04-15 2024-09-11 California Institute of Technology THERMAL CONTROL OF T-CELL IMMUNOTHERAPY BY MOLECULAR AND PHYSICAL ACTIVATION
WO2022029220A1 (en) 2020-08-05 2022-02-10 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
WO2022036265A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
US11999964B2 (en) 2020-08-28 2024-06-04 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
TW202237638A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
AU2022227021A1 (en) 2021-02-26 2023-09-21 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
US20250127896A1 (en) 2021-07-28 2025-04-24 Cero Therapeutics Holdings, Inc. Chimeric tim4 receptors and uses thereof
US20230391809A1 (en) * 2022-06-07 2023-12-07 Biomimetix Jv, Llc Hydrophobic compositions including a hydrophilic active ingredient and methods relating thereto
AU2023317584A1 (en) 2022-08-02 2025-02-13 Luca Science Inc. Methods of improving cellular therapy with organelle complexes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457105A (en) * 1992-01-20 1995-10-10 Zeneca Limited Quinazoline derivatives useful for treatment of neoplastic disease
WO1996009294A1 (en) * 1994-09-19 1996-03-28 The Wellcome Foundation Limited Substituted heteroaromatic compounds and their use in medicine
WO1996027797A2 (en) * 1995-03-08 1996-09-12 Hsc Research And Development Limited Partnership Zap 70 inhibitors and methods for treatment of zap 70 signal transduction disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457105A (en) * 1992-01-20 1995-10-10 Zeneca Limited Quinazoline derivatives useful for treatment of neoplastic disease
WO1996009294A1 (en) * 1994-09-19 1996-03-28 The Wellcome Foundation Limited Substituted heteroaromatic compounds and their use in medicine
WO1996027797A2 (en) * 1995-03-08 1996-09-12 Hsc Research And Development Limited Partnership Zap 70 inhibitors and methods for treatment of zap 70 signal transduction disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. LEVITZKI: "Receptor activation by antigens, cytokines, hormones and growth factors", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 766, 1995, pages 363 - 8, XP002053500 *
A. LEVITZKI: "Signal-transduction therapy", EUR. J. BIOCHEM., vol. 226, no. 1, 1994, pages 1 - 13, XP002053501 *
BEN-BASSAT ET AL: "Inhibitors of epidermal growth factor receptor kinase and cyclin dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes", CANCER RESEARCH, vol. 57, September 1997 (1997-09-01), pages 3741 - 50, XP002053502 *
BRIDGES ET AL: "Tyrosine kinase inhibitors. 8. An unusually step structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD153035), a potent inhibitor of the epidermal growth factor receptor", J MED CHEM, vol. 39, 1996, pages 267 - 76, XP002064936 *
TRAXLER ET AL: "4-Phenyl-amino(pyrrolopyrimidines): potent and selectzive,ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase", J. MED. CHEM., vol. 39, no. 12, December 1996 (1996-12-01), pages 2285 - 92, XP002053503 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42353E1 (en) 1996-09-25 2011-05-10 Astrazeneca Uk Limited Quinazoline derivatives and pharmaceutical compositions containing them
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
US9040548B2 (en) 1999-11-05 2015-05-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
US7160889B2 (en) 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds

Also Published As

Publication number Publication date
EP0954315A2 (en) 1999-11-10
WO1998010767A2 (en) 1998-03-19
AU4342997A (en) 1998-04-02
CA2265630A1 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
HUP9901807A3 (en) Heterocycle substituted n-acyl benzenesulfonamide derivatives, process for their preparation and their use as prodrug for the preparation of pharmaceutical compositions treating inflammation or inflammation-associated disorders
AU6974996A (en) Compositions for the treatment of dermatological disorders and methods for their use
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
IL127943A (en) Pharmaceutical and cosmetic compositions for the treatment of skin disorders
AU3990797A (en) Sustained release formulation
EP1806135A3 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
AU4342997A (en) Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
NZ504076A (en) A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition
WO2001051051A3 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
CA2392620A1 (en) Use of melatonin for the treatment of androgenetic and diffuse alopecia
CA2373794A1 (en) Compositions and uses of et743 for treating cancer
AU2001286562A1 (en) Use of agaricus blazei murill to prevent or treat skin and other disorders
CA2245766A1 (en) Compositions useful in the phototherapeutic treatment of proliferative skin disorders
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
CA2282682A1 (en) Tazarotene and corticosteroid treatment for psoriasis
IL145269A0 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
IL141515A0 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
AU7106300A (en) Treatment of skin disorders
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
IE870577L (en) Topical amide preparation
AU2509801A (en) Method for the cosmetic treatment of human skin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1-94, DESCRIPTION, REPLACED BY NEW PAGES 1-82; PAGES 95-111, CLAIMS, REPLACED BY NEW PAGES 83-97; PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

ENP Entry into the national phase

Ref document number: 2265630

Country of ref document: CA

Ref country code: CA

Ref document number: 2265630

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997941542

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998513877

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997941542

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997941542

Country of ref document: EP